DNA Damage Repair Therapy - Biomarker Guided

Overview

DNA Damage Repair Therapy is a biomarker-driven treatment strategy that targets impaired DNA repair mechanisms in neurodegenerative diseases. Elevated DNA damage markers guide therapy selection and monitoring.

[Neurons](/entities/neurons) are particularly vulnerable to DNA damage due to high metabolic activity and limited regenerative capacity. Accumulation of DNA lesions contributes to neuronal dysfunction and cell death in AD, PD, and other neurodegenerative conditions.

Mechanism of Action

Base excision repair enhancement - PARP1/2 modulators

Nucleotide excision repair support - XPA-XPC pathway activators

DNA strand break repair - ATM/ATR pathway modulators

Mitochondrial DNA protection - mtDNA repair enhancers

Measurable Biomarker Readouts

| Biomarker | Target | Measurement Method | Expected Change |
|-----------|--------|-------------------|-----------------|
| 8-OHdG (urine) | Decrease | LC-MS/MS | 40-60% reduction |
| 8-OHdG (CSF) | Decrease | ELISA | 30-50% reduction |
| gamma-H2AX | Decrease | Flow cytometry | 50-70% reduction |
| PAR levels | Normalize | ELISA | Return to baseline |
| Telomere length | Stabilize | qPCR | Prevent shortening |

DNA Damage Biomarkers

8-Hydroxy-2'-deoxyguanosine (8-OHdG)

• Marker of: Oxidative DNA damage
• Elevated in: AD, PD, ALS, Huntington's
• Correlation: Disease severity and progression

Gamma-H2AX

• Marker of: DNA double-strand breaks
• Elevated in: Ataxia telangiectasia, AD
• Therapeutic target: ATM pathway activation

...

Overview

DNA Damage Repair Therapy is a biomarker-driven treatment strategy that targets impaired DNA repair mechanisms in neurodegenerative diseases. Elevated DNA damage markers guide therapy selection and monitoring.

[Neurons](/entities/neurons) are particularly vulnerable to DNA damage due to high metabolic activity and limited regenerative capacity. Accumulation of DNA lesions contributes to neuronal dysfunction and cell death in AD, PD, and other neurodegenerative conditions.

Mechanism of Action

Base excision repair enhancement - PARP1/2 modulators

Nucleotide excision repair support - XPA-XPC pathway activators

DNA strand break repair - ATM/ATR pathway modulators

Mitochondrial DNA protection - mtDNA repair enhancers

Measurable Biomarker Readouts

| Biomarker | Target | Measurement Method | Expected Change |
|-----------|--------|-------------------|-----------------|
| 8-OHdG (urine) | Decrease | LC-MS/MS | 40-60% reduction |
| 8-OHdG (CSF) | Decrease | ELISA | 30-50% reduction |
| gamma-H2AX | Decrease | Flow cytometry | 50-70% reduction |
| PAR levels | Normalize | ELISA | Return to baseline |
| Telomere length | Stabilize | qPCR | Prevent shortening |

DNA Damage Biomarkers

8-Hydroxy-2'-deoxyguanosine (8-OHdG)

• Marker of: Oxidative DNA damage
• Elevated in: AD, PD, ALS, Huntington's
• Correlation: Disease severity and progression

Gamma-H2AX

• Marker of: DNA double-strand breaks
• Elevated in: Ataxia telangiectasia, AD
• Therapeutic target: ATM pathway activation

Poly(ADP-ribose) (PAR)

• Marker of: PARP activation (DNA repair attempt)
• Elevated in: Neurodegeneration
• Therapeutic target: PARP inhibition

Patient Selection

• Elevated baseline 8-OHdG (>10 ng/mL in urine)
• Evidence of DNA repair impairment
• Diagnosis of AD, PD, HD, or ALS
• Age 50-80 years

Therapeutic Candidates

PARP Inhibitors

• Olaparib - FDA-approved for cancer
• Niraparib - CNS penetration
• Rucaparib - Small molecule

DNA Repair Enhancers

• Nicotinamide riboside - NAD+ precursor
• Resveratrol - SIRT1 activator
• PQQ - Mitochondrial biogenesis

Antioxidants

• Edaravone - Free radical scavenger
• CoQ10 - Mitochondrial protection
• Methylene blue - Oxidative stress reducer

Clinical Trial Design

Biomarker Enrichment

Screen for elevated 8-OHdG or gamma-H2AX

Confirm DNA damage phenotype

Stratify by oxidative stress markers

Adaptive Trial Design

• Interim DNA damage biomarker analysis at 3 months
• Dose adjustment based on biomarker response
• Biomarker-guided patient stratification

Endpoints

• Primary: Change in urinary 8-OHdG at 12 months
• Secondary: Cognitive/motor scores, brain atrophy

Cross-Links

Related Biomarkers

• [DNA Damage Response in Alzheimer's Disease](/mechanisms/dna-damage-response-alzheimers)
• [Oxidative Stress Biomarkers](/biomarkers/oxidative-stress-biomarkers-overview)
• [NAD+ Metabolism in Neurodegeneration](/mechanisms/nad-metabolism-neurodegeneration)

Related Mechanisms

• [DNA Damage Repair in Neurodegeneration](/mechanisms/dna-damage-repair-neurodegeneration)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

Clinical Trials

• [DNA Damage Repair Therapy for Neurodegeneration](/therapeutics/dna-damage-repair-therapy)
• [Clinical Trials in Alzheimer's Disease](/clinical-trials/alzheimers-disease)

Monitoring Schedule

| Timepoint | Urine 8-OHdG | CSF 8-OHdG | PAR Levels | Clinical |
|-----------|--------------|------------|------------|----------|
| Baseline | Required | Optional | Required | Required |
| 3 months | Required | - | Optional | Required |
| 6 months | Required | Required | Required | Required |
| 12 months | Required | Required | Required | Required |

Challenges

[BBB](/entities/blood-brain-barrier) penetration - Many PARP inhibitors limited

Therapeutic window - PARP inhibition vs activation

Biomarker variability - 8-OHdG affected by diet/exercise

Chronic vs acute - Long-term treatment unknown

Combination Approaches

• PARP + NAD+ precursor - Synergistic DNA repair
• Antioxidant + PARP inhibitor - Reduce oxidative damage + enhance repair
• Mitochondrial + nuclear DNA - Target both compartments

Future Directions

• Blood-based DNA damage markers
• Gene therapy for DNA repair enzymes
• Personalized DNA damage profiles

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[@moreira2010]: [Moreira et al., DNA damage in Alzheimer's disease (2010)](https://doi.org/10.1016/j.jad.2009.08.031)
[@jha2015]: [Jha et al., PARP inhibitors in neurodegeneration (2015)](https://doi.org/10.1016/j.tips.2015.08.003)
[@sliwinska2020]: [Sliwinska et al., DNA repair in Parkinson's disease (2020)](https://doi.org/10.1016/j.neuropharm.2020.108019)
[@kennedy2020]: [Kennedy et al., NAD+ metabolism in aging and disease (2020)](https://doi.org/10.1038/s41580-020-00293-y)

Pathway Diagram

The following diagram shows key molecular relationships for DNA Damage Repair Therapy - Biomarker Guided based on knowledge graph edges:

Pathway Diagram

The following diagram shows the key molecular relationships involving DNA Damage Repair Therapy - Biomarker Guided discovered through SciDEX knowledge graph analysis: